New sequencing technologies are currently revolutionizing the field of genomic research. They enable researchers to investigate (epi)genomes and transcriptomes at an unexampled depth and level of detail.
Founded in 2007 the Next Generation Sequencing (NGS) Group at the Max Planck Institute for molecular Genetics (MPIMG) is a central unit which provides its service to all research groups of the institute. Since 2010 the expertise is also provided to scientists outside the MPIMG and the group acquired the status of a Sequencing Core Facility for all institutes of the biological-medical section (BMS) of the Max Planck Society.
The Sequencing Core Facility operates several next generation sequencers and maintains a fully equipped lab and staff able to perform a variety of sequencing applications - from sample preparation to data analysis. The NGS unit was founded to help researchers process DNA and RNA samples in an efficient and economical manner. We established automation solutions for the sample preparation to increase the throughput and minimize technical variation (Beckmann Spri-Te and 384 Beckman Multimek pipetting systems). By centralizing equipment and expertise, we have dramatically reduced the overall expense to the society, while increasing the efficiency and quality of the data generated. Currently we are providing expertise for two different technical platforms: Roche/454 FLX+ and Illumina Hiseq 2000/NextSeq 500 systems. At a read length of up to 1000 bases (modal read length around 800 bases) the 454 technology offers a great benefit especially for de novo genome sequencing, metagenome analysis, full length transcriptome analysis and amplicon sequencing. The high throughput of our Illumina systems in terms of Gigabases produced per run completes our sequencing service and offers a real advantage for many applications. Expression profiling (RNA-Seq), methylation analysis (MeDIP-Seq and Bisulphite-Seq), copy number analysis as well as the identification of protein binding sides (ChIP-Seq) and the analysis of whole exomes or genomes profite from the high output of this system to a great extent.